Phase 3Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease (ZUPREME-5)
A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardiovascular Disease
- Sponsor
- Hoffmann-La Roche (Industry)
- Enrolment
- 2,500 planned
- Conditions
- Obesity or Overweight; Cardiovascular Disease
- Interventions
- Petrelintide; Placebo
- Ages
- adults, older adults
- Registry
- NCT07843472, CTIS2026-526190-41-00
Full record on ClinicalTrials.gov
From the registry
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).
Primary outcomes
- Percentage Change in Body Weight from Baseline
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered